Dynavax Technologies Corporation
Dynavax Technologies Corporation (DVAX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
dvax · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Dynavax Technologies Corporation (DVAX) measures how much investors pay for each dollar of the company's trailing earnings. DVAX's current PE ratio of N/A is calculated by dividing its stock price of $15.50 by its TTM earnings per share of -$0.37.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%21.3x
MedianQ3 · 75%60.8x
Max
At N/A, DVAX's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Dynavax Technologies CorporationYou DVAX | $1.8B | N/A | — | -$0.37 |
 Amphastar Pharmaceuticals, Inc. AMPH | $855M | 12.76x | -29.3% | $2.10 |
 Beta Bionics, Inc. BBNX | $618M | N/A | — | -$1.81 |
 Collegium Pharmaceutical, Inc. COLL | $1.1B | 23.35x | +29.3% | $1.98 |
 Enliven Therapeutics, Inc. ELVN | $2.0B | N/A | — | -$1.83 |
 Evotec SE EVO | $998M | N/A | — | -$0.28 |
 Harrow Health, Inc. HROW | $1.2B | N/A | — | -$0.14 |
Industry Average 2 peers with valid PE | — | 18.06x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | 60.81x | $0.21 | — | |
2023-12-31 FY2023 | — | $-0.05 | — | |
2022-12-31 FY2022 | 4.59x | $2.32 | -78.5% | |
2021-12-31 FY2021 | 21.32x | $0.66 | — | |
2020-12-31 FY2020 | — | $-0.75 | — | |
2019-12-31 FY2019 | — | $-2.12 | — | |
2018-12-31 FY2018 | — | $-2.55 | — | |
2017-12-31 FY2017 | — | $-1.81 | — | |
2016-12-31 FY2016 | — | $-2.92 | — | |
2015-12-31 FY2015 | — | $-3.25 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Dynavax Technologies Corporation (DVAX) measures how much investors pay for each dollar of the company's trailing earnings. DVAX's current PE ratio of N/A is calculated by dividing its stock price of $15.50 by its TTM earnings per share of -$0.37.
Frequently asked questions
DVAX pe ratio · 6 questionsDVAX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $15.50 and TTM EPS of -$0.37. Data sourced from Financial Modeling Prep via DVAX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Dynavax Technologies Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08